Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Graft-versus-host Disease (GvHD)
44%
Acute Myeloid Leukemia
34%
Reduced-intensity Conditioning
29%
Stem Cell Transplantation
28%
Multiple Myeloma
26%
Working Party
26%
Non-relapse Mortality
25%
Acute Leukemia
24%
Marrow Transplantation
21%
Fludarabine
20%
Transplantation
19%
Leukemia Patients
18%
Overall Survival
16%
Complete Remission
16%
Hematopoietic Stem Cell Transplantation
15%
Hazard Ratio
15%
Conditioning Regimen
15%
Treosulfan
13%
Unrelated Donor
13%
Confidence Interval
12%
Chronic Myeloid Leukemia
11%
Myeloablative Conditioning
9%
Chimeric Antigen Receptor T Cells (CAR-T)
9%
Myelodysplastic Syndrome
9%
Relapsed or Refractory
9%
Hematological Malignancies
9%
Progression-free Survival
8%
Engraftment
8%
Antithymocyte Globulin
8%
Prognostic Factors
8%
Leukemia-free Survival
8%
Busulfan
8%
European Society
8%
Multivariate Analysis
8%
Donor Lymphocyte Infusion
8%
Intravenous Busulfan
8%
Remission
7%
Allogeneic Transplantation
7%
Chemotherapy
7%
Graft-versus-leukemia Effect
7%
Granulocyte Colony-stimulating Factor (G-CSF)
7%
Chimeric Antigen Receptor T-cell Therapy
7%
Anti-CD19 chimeric Antigen Receptor T Cells
7%
T Cells
7%
Myeloablative
6%
Relapse Rate
6%
Bone Marrow
6%
Adult Patients
6%
Relapsed or Refractory Acute Myeloid Leukemia
6%
Medicine and Dentistry
Allogeneic Stem Cell Transplantation
34%
Acute Myeloid Leukemia
33%
Disease
24%
Stem Cell Therapy
24%
Allogeneic Hematopoietic Stem Cell Transplantation
23%
Reduced Intensity Conditioning
23%
Conditioning
20%
Acute Leukemia
19%
Graft Versus Host Reaction
19%
Overall Survival
16%
Transplantation
16%
Fludarabine
15%
Multiple Myeloma
13%
Hazard Ratio
12%
Autologous Stem Cell Transplantation
11%
Acute Lymphoblastic Leukemia
11%
Busulfan
10%
Chimeric Antigen Receptor T-Cell
10%
Leukemia
10%
Cell Transplantation
9%
Hematopoietic Stem Cell
9%
Hematopoietic Stem Cell Transplantation
9%
Treosulfan
9%
Acute Graft Versus Host Disease
8%
Immunotherapy
8%
Progression Free Survival
8%
Myelodysplastic Syndrome
7%
Chronic Myelogenous Leukemia
7%
Prognostic Factor
7%
Cancer
7%
Chronic Graft Versus Host Disease
7%
Non-Hodgkin Lymphoma
7%
Cumulative Incidence
7%
Drug Megadose
7%
Donor Lymphocyte Infusion
7%
Myeloablative Conditioning
7%
Large-Cell Lymphoma
6%
Multivariate Analysis
6%
Minimal Residual Disease
6%
Chimeric Antigen Receptor T-Cell Immunotherapy
6%
Ibritumomab Tiuxetan
5%
Hematologic Malignancy
5%
Cyclophosphamide
5%
Engraftment
5%
T Cell
5%
Stem Cell
5%
Long Term Survival
5%
High Dose Chemotherapy
5%
Acute Myelogenous Leukemia
5%
Allotransplantation
5%
Immunology and Microbiology
Conditioning
40%
Allogeneic Stem Cell Transplantation
37%
Graft-Versus-Host Disease
30%
Myeloid
28%
Multiple Myeloma
27%
Allogeneic Hematopoietic Stem Cell Transplantation
25%
Transplant Procedure
22%
Stem Cell Transplantation
20%
Overall Survival
19%
Acute Graft Versus Host Disease
18%
T Cell
13%
Stem Cell
12%
Hematopoietic Stem Cell Transplantation
12%
Engraftment
11%
Hematopoietic Cell
11%
Chronic Graft Versus Host Disease
10%
Immunotherapy
10%
Cell Transplantation
9%
Cyclophosphamide
8%
Anti-Thymocyte Globulin
7%
Lymphocyte
7%
Allotransplantation
7%
B Cell
7%
Granulocyte Colony-Stimulating Factor
6%
Drug Megadose
6%
Autologous Stem Cell Transplantation
6%
CD19
5%
Mouse
5%
Single Nucleotide Polymorphism
5%
Progression Free Survival
5%
Chimeric Antigen Receptor T-Cell
5%
Hematopoietic Stem Cell
5%
Comorbidity
5%
Survival Rate
5%